Trial Profile
A Multicentre, Open-label Phase II Study of Nab-paclitaxel in Combination With Gemcitabine + Cisplatin as First Line Treatment in Patients With Unresectable Biliary Tract Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- Acronyms AX-CSARC
- 29 Jan 2024 Planned End Date changed from 1 Jun 2020 to 1 Jun 2024.
- 29 Jan 2024 Planned primary completion date changed from 1 Jun 2020 to 1 Jun 2024.
- 29 Jan 2024 Status changed from recruiting to active, no longer recruiting.